Skip to main content
AmigoFish

Derms on Drugs

Scholars in MedicineAudio

Format:
Podcast
New episodes:
Weekly
Typical length:
about 30 minutes
Latest episode:
Not rated yet

About this show

Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.

It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.

Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.

Covers: dermatology, medical education, clinical trials, hidradenitis suppurativa, atopic dermatitis, urticaria, hair loss, medical AI

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

Derms on Drugs is a podcast where three dermatologists discuss and debate current topics in skin medicine, aimed at clinicians. Recent episodes cover pyoderma gangrenosum, remibrutinib for chronic spontaneous urticaria, high-dose vitamin D, and AI-issued acne prescriptions in Utah.

Report a problem with this summary

Cosmos

Similar by topic and creator

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • The Ulcer Has Other Plans

    · 40 min

    A stubborn ulcer, a murky diagnosis, and the temptation to throw every drug at it. Dr. Ben Kaffenberger helps the Derms untangle pyoderma gangrenosum—from diagnostic traps to treatment choices and why a closed wound isn’t always a closed case.

    Not rated yet
  • Convince The Derms On Drugs: The Fast and the Urticarious

    · 23 min

    Dr. Jason Hawkes makes the case for putting speed first when choosing an advanced treatment for CSU. Remibrutinib works fast—but can he convince the Derms that fast is reason enough to put it first?

    Not rated yet
  • The Hills Are Alive With New Targets

    · 28 min

    The Derms stay in Vienna for round two of EADV, where zombie-cell cream meets new pathways in HS and AD—plus a JAK surprise in PPP and reassuring pregnancy data.

    Not rated yet
  • Better Croissants, Stranger Drugs

    · 33 min

    EADV serves up better croissants—and a packed menu of new mechanisms. The Derms dig into injectable RNA for BCC, a possible anti-scarring angle in HS, a TYK2 showdown, and an alopecia treatment that may keep working after treatment ends.

    Not rated yet
  • The Fast and the Urticarious

    · 23 min

    Dr. Jason Hawkes makes the case for putting speed first when choosing an advanced treatment for CSU. Remibrutinib works fast—but can he convince the Derms that fast is reason enough to put it first?

    Not rated yet
  • High D, Low Certainty

    · 32 min

    The Derms size up high-dose vitamin D, a head-to-head lichen planus trial, and whether contact dermatitis testing is overcalling the culprit.

    Not rated yet
  • Custom Shots and Drug Cocktails

    · 29 min

    The Derms question treatment monogamy: a personalized melanoma vaccine joins forces with immunotherapy, while dual therapy takes on refractory HS and AD.

    Not rated yet
  • AI Crosses the Prescription Line

    · 37 min

    In Utah, AI is getting its hands on the prescription pad—starting with topical acne treatment. The Derms grill Nolla’s CEO on the big questions: Who catches the misses, and is this better access or the beginning of the robot takeover?

    Not rated yet
  • The Goldilocks Biologic

    · 16 min

    Dr. Steve Daveluy makes the case that Cosentyx is the “just right” first biologic for HS—but not every Derm is ready to move past TNFs. Durability, infection risk, IBD, and insurance all enter the argument.

    Not rated yet
  • Tiny Vesicles, Big Claims

    · 37 min

    Exosomes may be real science, but the marketing has sprinted miles ahead of the data. The Derms dig into their promise for burns and epidermolysis bullosa—and why that pricey cosmetic vial may not contain what it claims.

    Not rated yet
  • Cuts, Switches, and Eight Extra Hairs

    · 27 min

    Three papers, three practical questions: Who really needs antibiotics before derm surgery? What comes after an AD drug fails? And does taking oral minoxidil in the morning actually grow more hair—or just raise more eyebrows?

    Not rated yet
  • Blood, Sweat, and Hives

    · 18 min

    Dr. Marc Serota makes the case for targeted lab testing in CSU—but the Derms worry it may open a can of worms. The Chronic Urticaria Index gets a closer look, shotgun allergy panels get nowhere—but does he convince the Derms?

    Not rated yet
  • Paging Dr. Telederm

    · 38 min

    After 70,000 virtual consults, Dr. Joe English knows what a photo can—and can’t—tell you. He joins the Derms to talk diagnostic curveballs, hospital saves, and bringing dermatology where there’s no dermatologist in sight.

    Not rated yet
  • Tregs, Tape, and Tresses

    · 28 min

    Three papers, three very different reactions: a Treg-boosting AD drug that may be too clever for its own good, a Steri-Strip trick you can use tomorrow, and Rinvoq alopecia data that have the Derms calling game changer.

    Not rated yet
  • Don’t Wait for the Tunnels

    · 18 min

    Convince the Derms on Drugs makes its debut with Dr. Christopher Sayed making the case for earlier systemic treatment in HS. Can he convince the Derms to act before recurring lesions become tunnels, scars, and damage no medication can undo?

    Not rated yet
  • Patch Me If You Can

    · 29 min

    Patch first or treat first? The Hamann brothers join the Derms to tackle mystery dermatitis, questionable allergens, wet wraps, hand eczema—and why the answer may be hiding in your patient’s shampoo.

    Not rated yet
  • The Clot Thickens

    · 33 min

    Three papers, three plot twists: new HS data that underwhelm on paper, a transected melanoma that may not need a sentinel node, and a possible explanation for why JAK clot risk may depend on the disease.

    Not rated yet
  • The Long and Short of Male Genital Disease

    · 41 min

    Male genital disease expert Dr. Christopher Bunker joins the Derms for the penis episode no one else was brave enough to make. Lichen sclerosus, circumcision, penile cancer—and one diagnosis he says doesn’t exist—are all on the table.

    Not rated yet
  • Three Sheets to Tofa

    · 32 min

    The Derms debut a shorter format with three papers and one newly dirt-cheap drug: generic tofacitinib. The safety, the risks, and the practicalities—right down to getting it for just $25 a month.

    Not rated yet
  • Creams, Screams, and Measles

    · 47 min

    Pediatric dermatology legend Dr. Sheila Fallon Friedlander joins the Derms to sort through the new topical “Goldilocks” problem, take the sting out of Dupixent injections, and make the case for treating molluscum sooner. Plus, how to recognize measles—and why its most frightening complication may not appear for years.

    Not rated yet